Europe Leukapheresis Market
No. of Pages: 132 | Report Code: TIPRE00025790 | Category: Life Sciences
No. of Pages: 132 | Report Code: TIPRE00025790 | Category: Life Sciences
The Europe Leukapheresis market is analyzed based on three large countries: Germany, the UK, France, Italy, Spain, and RoE. Germany is contributing a major share in the growth of leukapheresis market. Germany is an attractive market due to its steady growth and innovative approach to healthcare. According to the Federal Statistical Office, health expenditure in Germany in 2019 amounted to US$ 460.03 billion. The German medical device market is one of the largest in Europe and the third-largest in the world. The demand for highly innovative technologies and diagnostic, therapeutic, and minimally invasive devices remains high worldwide. Germany's medical device manufacturers can also apply for state funding for various research projects and receive grants from the Reconstruction Loan Corporation (KfW). Manufacturers' increasing focus on new product development and strategic collaborations to develop advanced diagnostic devices like leukapheresis is expected to fuel market growth. Germany has a strong health system, especially infrastructure, hospital beds, and trained staff. In 2018, according to the Ministry of Health, there were almost 498,400 beds in 1,925 hospitals, 1,142 rehabilitation centers, and 19,075 pharmacies. A well-developed infrastructure makes the health industry, with 5.6 million employees, the largest employer in Germany. In 2016, around 13,900 people in Germany contracted leukemia, 4% of them under 15. The risk decreases during the transition into young adulthood but increases again from the age of 30. These incidences are higher in men than in women. One in 67 men and one in 87 women will develop leukemia at some point in their lives.
The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Russia, Spain, Italy, Germany, France, and the UK are among the most affected European countries. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than they were during the first wave earlier this year. Lockdowns are being reintroduced in UK, Spain and Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, the government of many countries is working towards scaling up testing capacity, which is driving the growth of the market.
Strategic insights for the Europe Leukapheresis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 22.55 Million |
| Market Size by 2028 | US$ 39.26 Million |
| Global CAGR (2021 - 2028) | 8.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Leukapheresis refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The leukapheresis market in Europe is expected to grow from US$ 22.55 million in 2021 to US$ 39.26 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2021 to 2028. Therapeutic apheresis refers to an extracorporeal treatment that involves the selective removal of cells or other targeted abnormal substances from blood circulation. The technique has lately been explored for the treatment of various medical conditions. Extracorporeal photopheresis (ECP) is a process that is used in the treatment of lymphoma. In this process, white blood cells (WBCs) are collected from the bloodstream, treated with light-activated drugs, and exposed to UV lights, followed by infusing it back to the patient body. Therapeutic plasma exchange is a potential method employed to treat medical conditions such as multiple sclerosis, myeloma, and leukemia. The technique withdraws plasma from the patient’s blood and replaces it with fresh donor plasma or bottled human albumin solution. Further, the double filtration plasmapheresis technique is used for rapidly progressive glomerulonephritis and low-density lipoprotein (LDL) apheresis or leukocytapheresis for the nephritic syndrome. These techniques are two major apheresis therapies that are used to treat kidney diseases. Thus, the widening scope of apheresis technology in therapeutics is emerging as a prevalent trend in the leukapheresis market.
In terms of product type, the leukapheresis disposables segment held a larger share in 2021. Based on application, research applications segment held the largest share in 2021. Based on end user, blood component providers and blood centers segment held the largest share in 2021.
A few major primary and secondary sources referred to for preparing this report on the leukapheresis market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Asahi Kasei Corporation; Fresenius SE & Co. KGaA; Haemonetics Corporation; Terumo Corporation; STEMCELL Technologies Inc.; HemaCare; Macopharma; AllCells; STEMEXPRESS; and BioIVT among others.
The Europe Leukapheresis Market is valued at US$ 22.55 Million in 2021, it is projected to reach US$ 39.26 Million by 2028.
As per our report Europe Leukapheresis Market, the market size is valued at US$ 22.55 Million in 2021, projecting it to reach US$ 39.26 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.
The Europe Leukapheresis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Leukapheresis Market report:
The Europe Leukapheresis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Leukapheresis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Leukapheresis Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Leukapheresis Market
